304 related articles for article (PubMed ID: 31454099)
1. ATRX loss induces telomere dysfunction and necessitates induction of alternative lengthening of telomeres during human cell immortalization.
Li F; Deng Z; Zhang L; Wu C; Jin Y; Hwang I; Vladimirova O; Xu L; Yang L; Lu B; Dheekollu J; Li JY; Feng H; Hu J; Vakoc CR; Ying H; Paik J; Lieberman PM; Zheng H
EMBO J; 2019 Oct; 38(19):e96659. PubMed ID: 31454099
[TBL] [Abstract][Full Text] [Related]
2. Colorectal cancer patient-derived organoids and cell lines harboring ATRX and/or DAXX mutations lack Alternative Lengthening of Telomeres (ALT).
Falcinelli M; Dell'Omo G; Grassi E; Mariella E; Leto SM; Scardellato S; Lorenzato A; Arena S; Bertotti A; Trusolino L; Bardelli A; d'Adda di Fagagna F
Cell Death Dis; 2023 Feb; 14(2):96. PubMed ID: 36759506
[TBL] [Abstract][Full Text] [Related]
3. ATRX/DAXX: Guarding the Genome against the Hazards of ALT.
Clatterbuck Soper SF; Meltzer PS
Genes (Basel); 2023 Mar; 14(4):. PubMed ID: 37107548
[TBL] [Abstract][Full Text] [Related]
4. Rapid and reversible suppression of ALT by DAXX in osteosarcoma cells.
Yost KE; Clatterbuck Soper SF; Walker RL; Pineda MA; Zhu YJ; Ester CD; Showman S; Roschke AV; Waterfall JJ; Meltzer PS
Sci Rep; 2019 Mar; 9(1):4544. PubMed ID: 30872698
[TBL] [Abstract][Full Text] [Related]
5. Functional Loss of
Graham MK; Kim J; Da J; Brosnan-Cashman JA; Rizzo A; Baena Del Valle JA; Chia L; Rubenstein M; Davis C; Zheng Q; Cope L; Considine M; Haffner MC; De Marzo AM; Meeker AK; Heaphy CM
Mol Cancer Res; 2019 Dec; 17(12):2480-2491. PubMed ID: 31611308
[TBL] [Abstract][Full Text] [Related]
6. Loss of wild-type ATRX expression in somatic cell hybrids segregates with activation of Alternative Lengthening of Telomeres.
Bower K; Napier CE; Cole SL; Dagg RA; Lau LM; Duncan EL; Moy EL; Reddel RR
PLoS One; 2012; 7(11):e50062. PubMed ID: 23185534
[TBL] [Abstract][Full Text] [Related]
7. The chromatin remodeler complex ATRX-DAXX-H3.3 and telomere length in meningiomas.
Cavalcante SG; Pereira BJA; Lerario AM; Sola PR; Oba-Shinjo SM; Marie SKN
Clin Neurol Neurosurg; 2021 Nov; 210():106962. PubMed ID: 34624827
[TBL] [Abstract][Full Text] [Related]
8. ATRX affects the repair of telomeric DSBs by promoting cohesion and a DAXX-dependent activity.
Lovejoy CA; Takai K; Huh MS; Picketts DJ; de Lange T
PLoS Biol; 2020 Jan; 18(1):e3000594. PubMed ID: 31895940
[TBL] [Abstract][Full Text] [Related]
9. Alternative Lengthening of Telomeres and Loss of DAXX/ATRX Expression Predicts Metastatic Disease and Poor Survival in Patients with Pancreatic Neuroendocrine Tumors.
Singhi AD; Liu TC; Roncaioli JL; Cao D; Zeh HJ; Zureikat AH; Tsung A; Marsh JW; Lee KK; Hogg ME; Bahary N; Brand RE; McGrath KM; Slivka A; Cressman KL; Fuhrer K; O'Sullivan RJ
Clin Cancer Res; 2017 Jan; 23(2):600-609. PubMed ID: 27407094
[TBL] [Abstract][Full Text] [Related]
10. Loss of ATRX, genome instability, and an altered DNA damage response are hallmarks of the alternative lengthening of telomeres pathway.
Lovejoy CA; Li W; Reisenweber S; Thongthip S; Bruno J; de Lange T; De S; Petrini JH; Sung PA; Jasin M; Rosenbluh J; Zwang Y; Weir BA; Hatton C; Ivanova E; Macconaill L; Hanna M; Hahn WC; Lue NF; Reddel RR; Jiao Y; Kinzler K; Vogelstein B; Papadopoulos N; Meeker AK;
PLoS Genet; 2012; 8(7):e1002772. PubMed ID: 22829774
[TBL] [Abstract][Full Text] [Related]
11. Alternative lengthening of telomeres and loss of ATRX are frequent events in pleomorphic and dedifferentiated liposarcomas.
Lee JC; Jeng YM; Liau JY; Tsai JH; Hsu HH; Yang CY
Mod Pathol; 2015 Aug; 28(8):1064-73. PubMed ID: 26022452
[TBL] [Abstract][Full Text] [Related]
12. Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size.
Hackeng WM; Brosens LAA; Kim JY; O'Sullivan R; Sung YN; Liu TC; Cao D; Heayn M; Brosnan-Cashman J; An S; Morsink FHM; Heidsma CM; Valk GD; Vriens MR; Nieveen van Dijkum E; Offerhaus GJA; Dreijerink KMA; Zeh H; Zureikat AH; Hogg M; Lee K; Geller D; Marsh JW; Paniccia A; Ongchin M; Pingpank JF; Bahary N; Aijazi M; Brand R; Chennat J; Das R; Fasanella KE; Khalid A; McGrath K; Sarkaria S; Singh H; Slivka A; Nalesnik M; Han X; Nikiforova MN; Lawlor RT; Mafficini A; Rusev B; Corbo V; Luchini C; Bersani S; Pea A; Cingarlini S; Landoni L; Salvia R; Milione M; Milella M; Scarpa A; Hong SM; Heaphy CM; Singhi AD
Gut; 2022 May; 71(5):961-973. PubMed ID: 33849943
[TBL] [Abstract][Full Text] [Related]
13. ATRX proximal protein associations boast roles beyond histone deposition.
Scott WA; Dhanji EZ; Dyakov BJA; Dreseris ES; Asa JS; Grange LJ; Mirceta M; Pearson CE; Stewart GS; Gingras AC; Campos EI
PLoS Genet; 2021 Nov; 17(11):e1009909. PubMed ID: 34780483
[TBL] [Abstract][Full Text] [Related]
14. Alternative lengthening of telomeres and ATRX/DAXX loss can be reliably detected in FNAs of pancreatic neuroendocrine tumors.
VandenBussche CJ; Allison DB; Graham MK; Charu V; Lennon AM; Wolfgang CL; Hruban RH; Heaphy CM
Cancer Cytopathol; 2017 Jul; 125(7):544-551. PubMed ID: 28371511
[TBL] [Abstract][Full Text] [Related]
15. The macroH2A1.2 histone variant links ATRX loss to alternative telomere lengthening.
Kim J; Sun C; Tran AD; Chin PJ; Ruiz PD; Wang K; Gibbons RJ; Gamble MJ; Liu Y; Oberdoerffer P
Nat Struct Mol Biol; 2019 Mar; 26(3):213-219. PubMed ID: 30833786
[TBL] [Abstract][Full Text] [Related]
16. Endoscopic ultrasound fine-needle biopsy to assess DAXX/ATRX expression and alternative lengthening of telomeres status in non-functional pancreatic neuroendocrine tumors.
Mastrosimini MG; Manfrin E; Remo A; De Bellis M; Parisi A; Pedron S; Luchini C; Brunelli M; Ammendola S; Bernardoni L; Conti Bellocchi MC; Gabbrielli A; Facciorusso A; Pea A; Landoni L; Scarpa A; Crinò SF
Pancreatology; 2023 Jun; 23(4):429-436. PubMed ID: 37169669
[TBL] [Abstract][Full Text] [Related]
17. Suppression of the alternative lengthening of telomere pathway by the chromatin remodelling factor ATRX.
Clynes D; Jelinska C; Xella B; Ayyub H; Scott C; Mitson M; Taylor S; Higgs DR; Gibbons RJ
Nat Commun; 2015 Jul; 6():7538. PubMed ID: 26143912
[TBL] [Abstract][Full Text] [Related]
18. ATRX loss induces multiple hallmarks of the alternative lengthening of telomeres (ALT) phenotype in human glioma cell lines in a cell line-specific manner.
Brosnan-Cashman JA; Yuan M; Graham MK; Rizzo AJ; Myers KM; Davis C; Zhang R; Esopi DM; Raabe EH; Eberhart CG; Heaphy CM; Meeker AK
PLoS One; 2018; 13(9):e0204159. PubMed ID: 30226859
[TBL] [Abstract][Full Text] [Related]
19. Loss of ATRX or DAXX expression and concomitant acquisition of the alternative lengthening of telomeres phenotype are late events in a small subset of MEN-1 syndrome pancreatic neuroendocrine tumors.
de Wilde RF; Heaphy CM; Maitra A; Meeker AK; Edil BH; Wolfgang CL; Ellison TA; Schulick RD; Molenaar IQ; Valk GD; Vriens MR; Borel Rinkes IH; Offerhaus GJ; Hruban RH; Matsukuma KE
Mod Pathol; 2012 Jul; 25(7):1033-9. PubMed ID: 22575867
[TBL] [Abstract][Full Text] [Related]
20. Switch telomerase to ALT mechanism by inducing telomeric DNA damages and dysfunction of ATRX and DAXX.
Hu Y; Shi G; Zhang L; Li F; Jiang Y; Jiang S; Ma W; Zhao Y; Songyang Z; Huang J
Sci Rep; 2016 Aug; 6():32280. PubMed ID: 27578458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
